Patent ID: 8784821
Filing Date: 2014-07-22
Classification: A61K,C07K

Abstract:
1. A purified binding molecule specifically binding to/interacting with the human CD3 complex, whereby said binding molecule is an antibody molecule, antibody fragment or derivative thereof or an antibody construct, wherein said antibody molecule, antibody fragment or derivative thereof or an antibody construct comprises a CDR1, CDR2 and CDR3 region, wherein said CDR regions comprise: a) VH-region CDR1, CDR2 and CDR3 as encoded by a nucleic acid molecule as shown in SEQ ID NOs: 3, 5, and 7 or having the amino acid sequence as shown in SEQ ID NOs: 4, 6, and 8 and VL-region CDR1, CDR2 and CDR3 as encoded by a nucleic acid molecule as shown in SEQ ID NOs: 11, 13, 15 or having the amino acid sequence as shown in SEQ ID NOs: 12, 14, and 16; b) VH-region CDR1, CDR2 and CDR3 as encoded by a nucleic acid molecule as shown in SEQ ID NOs: 19, 21, and 23 or having the amino acid sequence as shown in SEQ ID NOs: 20, 22, and 24 and VL-region CDR1, CDR2 and CDR3 as encoded by a nucleic acid molecule as shown in SEQ ID NOs: 27, 29, 31 or having the amino acid sequence as shown in SEQ ID NOs: 28, 30, and 32; c) VH-region CDR1, CDR2 and CDR3 as encoded by a nucleic acid molecule as shown in SEQ ID NOs: 35, 37, and 39 or having the amino acid sequence as shown in SEQ ID NOs: 36, 38, and 40 and VL-region CDR1, CDR2 and CDR3 as encoded by a nucleic acid molecule as shown in SEQ ID NOs: 43, 45, 47 or having the amino acid sequence as shown in SEQ ID NOs: 44, 46, and 48; d) VH-region CDR1, CDR2 and CDR3 as encoded by a nucleic acid molecule as shown in SEQ ID NOs: 51, 53, and 55 or having the amino acid sequence as shown in SEQ ID NOs: 52, 54, and 56 and VL-region CDR1, CDR2 and CDR3 as encoded by a nucleic acid molecule as shown in SEQ ID NOs: 59, 61, 63 or having the amino acid sequence as shown in SEQ ID NOs: 60, 62, and 64; e) VH-region CDR1, CDR2 and CDR3 as encoded by a nucleic acid molecule as shown in SEQ ID NOs: 67, 69, and 71 or having the amino acid sequence as shown in SEQ ID NOs: 68, 70 and 72 and VL-region CDR1, CDR2 and CDR3 as encoded by a nucleic acid molecule as shown in SEQ ID NOs: 75, 77, 79 or having the amino acid sequence as shown in SEQ ID NOs: 76, 78, and 80; f) VH-region CDR1, CDR2 and CDR3 as encoded by a nucleic acid molecule as shown in SEQ ID NOs: 83, 85, and 87 or having the amino acid sequence as shown in SEQ ID NOs: 84, 86, and 88 and VL-region CDR1, CDR2 and CDR3 as encoded by a nucleic acid molecule as shown in SEQ ID NOs: 91, 93, 95 or having the amino acid sequence as shown in SEQ ID NOs: 92, 94, and 96; g) VH-region CDR1, CDR2 and CDR3 as encoded by a nucleic acid molecule as shown in SEQ ID NOs: 99, 101, and 103 or having the amino acid sequence as shown in SEQ ID NOs: 100, 102, and 104 and VL-region CDR1, CDR2 and CDR3 as encoded by a nucleic acid molecule as shown in SEQ ID NOs: 107, 109, 111 or having the amino acid sequence as shown in SEQ ID NOs: 108, 110, and 112; or h) VH-region CDR1, CDR2 and CDR3 as encoded by a nucleic acid molecule as shown in SEQ ID NOs: 115, 117, and 119 or having the amino acid sequence as shown in SEQ ID NOs: 116, 118, and 120 and VL-region CDR1, CDR2 and CDR3 as encoded by a nucleic acid molecule as shown in SEQ ID NOs: 123, 125, 127 or having the amino acid sequence as shown in SEQ ID NOs: 124, 126, and 128.